BioAge Labs announced the pricing and expected closing of an upsized underwritten public offering of 5,897,435 shares, generating approximately $115.0 million in gross proceeds before expenses. The underwriters, led by Goldman Sachs, Piper Sandler and Citigroup, also received a 30-day option to purchase up to 884,615 additional shares. The offering is scheduled to close on January 23, 2026, subject to customary conditions. BioAge plans to apply the net proceeds, in conjunction with existing cash and marketable securities, toward research, clinical development and manufacturing of its lead candidate BGE-102 and its APJ agonist programs, as well as working capital, capital expenditures, debt reduction and other corporate purposes.

On January 20, 2026, BioAge had filed for a proposed underwritten offering of up to $75.0 million of common stock, with an over-allotment option of $11.25 million. At that time, the company noted the proceeds would fund R&D and process development for BGE-102 and its NLRP3 and APJ programs, mirroring the stated uses in the subsequent upsized deal. The earlier filing under Form S-3 became effective in November 2025, and materials for investors were to be made available via Goldman Sachs, Piper Sandler and Citigroup, and on the SEC’s website.

BioAge has broadened the development of its oral NLRP3 inhibitor BGE-102 into diabetic macular edema (DME), launching a Phase 1b/2a proof-of-concept study in mid-2026. In preclinical DME models, oral dosing preserved up to 90% of microvascular integrity and nearly eliminated retinal vascular leakage. In ongoing Phase 1 SAD/MAD trials, BGE-102 demonstrated favorable tolerability and robust reductions in key inflammatory biomarkers (hsCRP, IL-6, IL-1β). The randomized DME trial will assess intraocular IL-6 reduction, visual acuity and retinal thickness, with readout expected mid-2027. This program will run alongside a Phase 2a cardiovascular risk study, with results due in the second half of 2026.